Inflammation therapeutic biosimilar - Zydus Cadila
Alternative Names: Prod 3Latest Information Update: 28 Mar 2023
At a glance
- Originator Zydus Cadila
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation; Myocardial infarction
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Myocardial infarction in India (Parenteral)
- 28 Mar 2023 Discontinued for Inflammation in India (unspecified route)
- 22 Oct 2015 Early research in Inflammation in India (unspecified route) before October 2015 (Zydus pipeline, October 2015)